Response to: “Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration's September 1, 2021, data safety communication”

Jonathan W. Rick, Peter Lio, Jennifer L. Hsiao, Vivian Y. Shi

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)e33-e34
JournalJournal of the American Academy of Dermatology
Issue number1
StatePublished - Jul 2022
Externally publishedYes

Cite this